loading page

Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low grade glioma
  • +3
  • Musthafa Raswoli,
  • Liana Nobre,
  • Cynthia Hawkins,
  • Ute Bartels,
  • Uri Tabori,
  • Eric Bouffet
Musthafa Raswoli
Hospital for Sick Children
Author Profile
Liana Nobre
Hospital for Sick Children
Author Profile
Cynthia Hawkins
The Hospital for Sick Children
Author Profile
Ute Bartels
The Hospital for Sick Children
Author Profile
Uri Tabori
The Hospital for Sick Children , toronto
Author Profile
Eric Bouffet
Hospital for Sick Children
Author Profile

Abstract

Targeted therapies are increasingly used in the management of pediatric low grade glioma. How-ever for patients who show resistance to these treatments, limited options are available. We pre-sent the case of a patient with BRAFV600 mutated low grade glioma who showed progression on a combination of trametinib and dabrafenib. Discontinuation of treatment was associated with a life-threatening deterioration and reintroduction of targeted therapy had no effect. The patient eventually showed a dramatic response to TPCV (thiguanine, procarbazine, CCNU and vincris-tine) , which suggests a role of chemotherapy in these situations.

Peer review status:Published

18 Jul 2020Published in Pediatric Blood & Cancer. 10.1002/pbc.28561